Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice.

Heckl BC, Carlet M, Vick B, Roolf C, Alsadeq A, Grunert M, Liu WH, Liebl A, Hiddemann W, Marschalek R, Schewe DM, Spiekermann K, Junghanss C, Jeremias I.

Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509314. [Epub ahead of print] No abstract available.

PMID:
30234406
2.

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia.

Kellner C, Peipp M, Gramatzki M, Schrappe M, Schewe DM.

Oncoimmunology. 2018 Apr 9;7(8):e1448331. doi: 10.1080/2162402X.2018.1448331. eCollection 2018.

3.

IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.

Alsadeq A, Lenk L, Vadakumchery A, Cousins A, Vokuhl C, Khadour A, Vogiatzi F, Seyfried F, Meyer LH, Cario G, Hobeika E, Debatin KM, Halsey C, Schrappe M, Schewe DM, Jumaa H.

Blood. 2018 Oct 11;132(15):1614-1617. doi: 10.1182/blood-2018-04-844209. Epub 2018 Aug 28. No abstract available.

PMID:
30154115
4.

"Mouse-MRD" in central nervous system acute lymphoblastic leukaemia: assessing bone marrow minimal residual disease using a xenograft model - from bedside to the bench and back again.

Alten J, Claviez A, Vieth S, Cario G, Schewe DM.

Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15024. [Epub ahead of print] No abstract available.

PMID:
29193025
5.

The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia.

Fedders H, Alsadeq A, Schmäh J, Vogiatzi F, Zimmermann M, Möricke A, Lenk L, Stadt UZ, Horstmann MA, Pieters R, Schrappe M, Stanulla M, Cario G, Schewe DM.

Haematologica. 2017 Nov;102(11):e438-e442. doi: 10.3324/haematol.2017.169870. Epub 2017 Aug 24. No abstract available.

6.

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.

Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C.

Blood. 2017 Sep 28;130(13):1543-1552. doi: 10.1182/blood-2017-01-764316. Epub 2017 Jul 11.

7.

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. No abstract available.

PMID:
28449349
8.

Acute lymphoblastic leukemia of the central nervous system: on the role of PBX1.

Alsadeq A, Schewe DM.

Haematologica. 2017 Apr;102(4):611-613. doi: 10.3324/haematol.2017.165142. No abstract available.

9.

The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system.

Alsadeq A, Fedders H, Vokuhl C, Belau NM, Zimmermann M, Wirbelauer T, Spielberg S, Vossen-Gajcy M, Cario G, Schrappe M, Schewe DM.

Haematologica. 2017 Feb;102(2):346-355. doi: 10.3324/haematol.2016.147744. Epub 2016 Sep 29.

10.

Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

Alsadeq A, Strube S, Krause S, Carlet M, Jeremias I, Vokuhl C, Loges S, Aguirre-Ghiso JA, Trauzold A, Cario G, Stanulla M, Schrappe M, Schewe DM.

Leukemia. 2015 Dec;29(12):2307-16. doi: 10.1038/leu.2015.153. Epub 2015 Jun 24.

11.

Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.

Adomako A, Calvo V, Biran N, Osman K, Chari A, Paton JC, Paton AW, Moore K, Schewe DM, Aguirre-Ghiso JA.

BMC Cancer. 2015 May 30;15:444. doi: 10.1186/s12885-015-1460-1.

12.

Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, Muench V, Bruckmueller H, Vokuhl C, Debatin KM, Eckert C, Stanulla M, Schrappe M, Campbell KS, Loewenthal R, Schewe DM, Hochman J, Meyer LH, Kaufman D, Cario G, Porgador A, Izraeli S.

Blood. 2015 May 28;125(22):3420-31. doi: 10.1182/blood-2014-08-595108. Epub 2015 Apr 20. Erratum in: Blood. 2015 Jul 16;126(3):425.

13.

Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).

Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, Loges S, Waizenegger J, Ben-Batalla I, Cario G, Möricke A, Stanulla M, Schrappe M, Schewe DM.

Blood. 2015 Jan 29;125(5):820-30. doi: 10.1182/blood-2014-06-583062. Epub 2014 Nov 26.

14.

TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling.

Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, Schewe DM, Aguirre-Ghiso JA.

Nat Cell Biol. 2013 Nov;15(11):1351-61. doi: 10.1038/ncb2861. Epub 2013 Oct 27.

15.

Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.

Schewe DM, Aguirre-Ghiso JA.

Cancer Res. 2009 Feb 15;69(4):1545-52. doi: 10.1158/0008-5472.CAN-08-3858. Epub 2009 Feb 3.

16.

ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo.

Schewe DM, Aguirre-Ghiso JA.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10519-24. doi: 10.1073/pnas.0800939105. Epub 2008 Jul 23.

17.

Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer.

Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S, Allgayer H.

Clin Cancer Res. 2007 Feb 15;13(4):1123-32.

18.
19.

Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.

Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H.

Clin Cancer Res. 2003 Jun;9(6):2267-76.

Supplemental Content

Loading ...
Support Center